Your browser doesn't support javascript.
loading
Molecular characteristics of early-onset pancreatic ductal adenocarcinoma.
Debernardi, Silvana; Liszka, Lukasz; Ntala, Chara; Steiger, Katja; Esposito, Irene; Carlotti, Emanuela; Baker, Ann-Marie; McDonald, Stuart; Graham, Trevor; Dmitrovic, Branko; Feakins, Roger M; Crnogorac-Jurcevic, Tatjana.
Afiliación
  • Debernardi S; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, UK.
  • Liszka L; Department of Pathomorphology and Molecular Diagnostics, Medical University of Silesia, Katowice, Poland.
  • Ntala C; St Georges University Hospital, London, UK.
  • Steiger K; Institute of Pathology, School of Medicine and Health, Technical University of Munich, Germany.
  • Esposito I; Institute of Pathology, Heinrich-Heine University and University Hospital of Dusseldorf, Germany.
  • Carlotti E; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, UK.
  • Baker AM; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, UK.
  • McDonald S; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, UK.
  • Graham T; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, UK.
  • Dmitrovic B; Department of Pathology and Forensic Medicine, Clinical Hospital Center Osijek, Croatia.
  • Feakins RM; Department of Cellular Pathology, Royal Free London NHS Foundation Trust, UK.
  • Crnogorac-Jurcevic T; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, UK.
Mol Oncol ; 18(3): 677-690, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38145461
ABSTRACT
The median age of patients with pancreatic ductal adenocarcinoma (PDAC) at diagnosis is 71 years; however, around 10% present with early-onset pancreatic cancer (EOPC), i.e., before age 50. The molecular mechanisms underlying such an early onset are unknown. We assessed the role of common PDAC drivers (KRAS, TP53, CDKN2A and SMAD4) and determined their mutational status and protein expression in 90 formalin-fixed, paraffin-embedded tissues, including multiple primary and matched metastases, from 37 EOPC patients. KRAS was mutated in 88% of patients; p53 was altered in 94%, and p16 and SMAD4 were lost in 86% and 71% of patients, respectively. Meta-synthesis showed a higher rate of p53 alterations in EOPC than in late-onset PDAC (94% vs. 69%, P = 0.0009) and significantly higher loss of SMAD4 (71% vs. 44%, P = 0.0025). The majority of EOPC patients accumulated aberrations in all four drivers; in addition, high tumour heterogeneity was observed across all tissues. The cumulative effect of an exceptionally high rate of alterations in all common PDAC driver genes combined with high tumour heterogeneity suggests an important mechanism underlying the early onset of PDAC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático Límite: Aged / Humans / Middle aged Idioma: En Revista: Mol Oncol Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático Límite: Aged / Humans / Middle aged Idioma: En Revista: Mol Oncol Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido